Clinical Progress AB Science has an active oncology and non-oncology clinical program with Phase 2 and Phase 3 trials for masitinib, plus a Phase 3 ALS program launched in 2025. This signals ongoing demand generation opportunities with hospitals, research centers, and payer stakeholders evaluating new therapies.

Targeted Therapies Specialization in tyrosine kinase inhibitors for cancers, inflammatory diseases, and neurological disorders positions AB Science to partner on companion diagnostics, biomarker strategy, and alignable trial sites focusing on high-need patient populations.

Veterinary Expansion Lead compound commercialization in Veterinary Medicine creates cross-channel sales and co-promotion possibilities with veterinary clinics and distributors, offering a foothold to leverage ADME/tox data and repurpose messaging for ancillary markets.

Financial Health With substantial revenue and a $60M funding base, AB Science demonstrates funding readiness for partnerships, licensing deals, or milestone-based collaborations to accelerate late-stage development and expand clinical trial networks.

Global Partnerships Past collaborations with prestigious institutions and involvement in European MS and ALS programs indicate openness to research alliances, licensing, and co-development agreements with pharma and academic partners to accelerate access and diversify risk.